Sugi Predict

Sugi Predict / Compounds / SCHEMBL25318634

SCHEMBL25318634

SCHEMBL25318634

CS(=O)(=O)c1c(F)cc(OCCN2CCC3(CC2)C(=O)Nc2ccc(Cl)cc23)cc1F

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HTR7 P34969 8/20 0.42
▸ IP6K1 Q92551 8/20 0.42
▸ HTR1A P08908 7/20 0.42
▸ HTR2A P28223 7/20 0.42
▸ HTR6 P50406 7/20 0.42
▸ MET P08581 2/20 0.39
▸ IP6K3 Q96PC2 1/20 0.39
▸ IP6K2 Q9UHH9 1/20 0.39
▸ LMNA P02545 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ DRD2 P14416 1/20 0.38
▸ ADRA1D P25100 1/20 0.38
▸ SLC6A4 P31645 1/20 0.38
▸ ADRA1A P35348 1/20 0.38
▸ ADRA1B P35368 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30507195 1.00 HTR7 (0.42) HTR7IP6K1HTR1AHTR2AHTR6
SCHEMBL25318430 0.90 IP6K1 (0.42) HTR7IP6K1HTR1AHTR2AHTR6
SCHEMBL30507265 0.90 IP6K1 (0.42) HTR7IP6K1HTR1AHTR2AHTR6
SCHEMBL30506845 0.89 HTR1A (0.41) HTR7IP6K1HTR1AHTR2AHTR6
SCHEMBL25316213 0.89 HTR1A (0.41) HTR7IP6K1HTR1AHTR2AHTR6
SCHEMBL30507382 0.89 MET (0.41) HTR7IP6K1HTR1AHTR2AHTR6
SCHEMBL25316933 0.89 MET (0.41) HTR7IP6K1HTR1AHTR2AHTR6
SCHEMBL25315817 0.89 MET (0.41) HTR7IP6K1HTR1AHTR2AHTR6
SCHEMBL25315813 0.89 MET (0.41) HTR7IP6K1HTR1AHTR2AHTR6
SCHEMBL30507077 0.89 MET (0.41) HTR7IP6K1HTR1AHTR2AHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282781-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2025-09-11 — — US disclosed
US-12344610-B2 APOL1 inhibitors and methods of use MAZE THERAPEUTICS, INC. (US) 2025-07-01 — — US disclosed
US-20240400565-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2024-12-05 — — US disclosed
US-11976067-B2 APOL1 inhibitors and methods of use MAZE THERAPEUTICS, INC. (US) 2024-05-07 — — US disclosed
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2023-08-24 — — US disclosed
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2023-08-24 — — US disclosed
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2023-08-24 — — US disclosed
WO-2023141432-A2 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS, INC. (US) 2023-07-27 — — WO disclosed
WO-2023141432-A2 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS, INC. (US) 2023-07-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, LDLR HTR7 3454/4885IP6K1 3004/4885HTR1A 1681/4885
US-12344610-B2 APOL1 inhibitors and methods of use APOL1, APOB, PON1 HTR7 3390/4885IP6K1 3034/4885HTR1A 1745/4885
US-11976067-B2 APOL1 inhibitors and methods of use APOL1, APOB, LDLR HTR7 3454/4885IP6K1 3004/4885HTR1A 1681/4885
US-20250282781-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, PON1 HTR7 3390/4885IP6K1 3034/4885HTR1A 1745/4885
US-20240400565-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, PON1 HTR7 3390/4885IP6K1 3034/4885HTR1A 1745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.